Inhibitory Effect of NO-releasing Ciprofloxacin (NCX 976) on Mycobacterium Tuberculosis Survival

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2003 Jun 25

PMID 12821482

Citations 5

Authors

R Ciccone

F Mariani

A Cavone

T Persichini

G Venturini

E Ongini

V Colizzi

M Colasanti

Affiliations

Soon will be listed here.

Abstract

Here, we report the antimycobacterial activity of NCX 976, a new molecule obtained adding a NO moiety to the fluoroquinolone ciprofloxacin, on Mycobacterium tuberculosis H37Rv strain, both in a cell-free model and in infected human macrophages. Unlike unaltered ciprofloxacin, NCX976 displayed a marked activity also at low-nanomolar concentrations.

Citing Articles

Reinforcing the Functionality of Mononuclear Phagocyte System to Control Tuberculosis.

Pahari S, Kaur G, Negi S, Aqdas M, Das D, Bashir H Front Immunol. 2018; 9:193.

PMID: 29479353 PMC: 5811511. DOI: 10.3389/fimmu.2018.00193.

Innate Immunity Holding the Flanks until Reinforced by Adaptive Immunity against Mycobacterium tuberculosis Infection.

Khan N, Vidyarthi A, Javed S, Agrewala J Front Microbiol. 2016; 7:328.

PMID: 27014247 PMC: 4789502. DOI: 10.3389/fmicb.2016.00328.

The role of airway epithelial cells in response to mycobacteria infection.

Li Y, Wang Y, Liu X Clin Dev Immunol. 2012; 2012:791392.

PMID: 22570668 PMC: 3337601. DOI: 10.1155/2012/791392.

Requirements for nitric oxide generation from isoniazid activation in vitro and inhibition of mycobacterial respiration in vivo.

Timmins G, Master S, Rusnak F, Deretic V J Bacteriol. 2004; 186(16):5427-31.

PMID: 15292144 PMC: 490879. DOI: 10.1128/JB.186.16.5427-5431.2004.

Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis.

Timmins G, Master S, Rusnak F, Deretic V Antimicrob Agents Chemother. 2004; 48(8):3006-9.

PMID: 15273113 PMC: 478481. DOI: 10.1128/AAC.48.8.3006-3009.2004.

References

Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S . Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother. 2000; 44(2):283-6. PMC: 89672. DOI: 10.1128/AAC.44.2.283-286.2000. View

Zahrt T, Deretic V . Reactive nitrogen and oxygen intermediates and bacterial defenses: unusual adaptations in Mycobacterium tuberculosis. Antioxid Redox Signal. 2002; 4(1):141-59. DOI: 10.1089/152308602753625924. View

Alangaden G, Lerner S . The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin Infect Dis. 1997; 25(5):1213-21. DOI: 10.1086/516116. View

Long R, Light B, Talbot J . Mycobacteriocidal action of exogenous nitric oxide. Antimicrob Agents Chemother. 1999; 43(2):403-5. PMC: 89090. DOI: 10.1128/AAC.43.2.403. View

Hu Y, Butcher P, Mangan J, Rajandream M, Coates A . Regulation of hmp gene transcription in Mycobacterium tuberculosis: effects of oxygen limitation and nitrosative and oxidative stress. J Bacteriol. 1999; 181(11):3486-93. PMC: 93817. DOI: 10.1128/JB.181.11.3486-3493.1999. View

Del Soldato P, Sorrentino R, Pinto A . NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci. 1999; 20(8):319-23. DOI: 10.1016/s0165-6147(99)01353-x. View

Couture M, Yeh S, Wittenberg B, Wittenberg J, Ouellet Y, Rousseau D . A cooperative oxygen-binding hemoglobin from Mycobacterium tuberculosis. Proc Natl Acad Sci U S A. 1999; 96(20):11223-8. PMC: 18015. DOI: 10.1073/pnas.96.20.11223. View

Clark I, Rockett K . Nitric oxide and parasitic disease. Adv Parasitol. 1996; 37:1-56. DOI: 10.1016/s0065-308x(08)60218-3. View

Shiloh M, Nathan C . Reactive nitrogen intermediates and the pathogenesis of Salmonella and mycobacteria. Curr Opin Microbiol. 2000; 3(1):35-42. DOI: 10.1016/s1369-5274(99)00048-x. View

10.

Colasanti M, Persichini T, Venturini G, Ascenzi P . S-nitrosylation of viral proteins: molecular bases for antiviral effect of nitric oxide. IUBMB Life. 2000; 48(1):25-31. DOI: 10.1080/713803459. View

11.

Nathan C, Shiloh M . Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci U S A. 2000; 97(16):8841-8. PMC: 34021. DOI: 10.1073/pnas.97.16.8841. View

12.

Mariani F, Cappelli G, Riccardi G, Colizzi V . Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage. Gene. 2000; 253(2):281-91. DOI: 10.1016/s0378-1119(00)00249-3. View

13.

Akaike T, Maeda H . Nitric oxide and virus infection. Immunology. 2000; 101(3):300-8. PMC: 2327086. DOI: 10.1046/j.1365-2567.2000.00142.x. View

14.

Raupach B, Kaufmann S . Immune responses to intracellular bacteria. Curr Opin Immunol. 2001; 13(4):417-28. DOI: 10.1016/s0952-7915(00)00236-3. View

15.

Huttunen K, Jussila J, Hirvonen M, Iivanainen E, Katila M . Comparison of mycobacteria-induced cytotoxicity and inflammatory responses in human and mouse cell lines. Inhal Toxicol. 2001; 13(11):977-91. DOI: 10.1080/089583701753210362. View

16.

Scanga C, Mohan V, Tanaka K, Alland D, Flynn J, Chan J . The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect Immun. 2001; 69(12):7711-7. PMC: 98866. DOI: 10.1128/IAI.69.12.7711-7717.2001. View

17.

Chan E, Chan J, Schluger N . What is the role of nitric oxide in murine and human host defense against tuberculosis?Current knowledge. Am J Respir Cell Mol Biol. 2001; 25(5):606-12. DOI: 10.1165/ajrcmb.25.5.4487. View

18.

Tomioka H . Prospects for development of new antimycobacterial drugs. J Infect Chemother. 2002; 6(1):8-20. DOI: 10.1007/s101560050043. View